Polaryx Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Landis G. Michael, was filed 20 Feb 2026.
Polaryx Therapeutics, Inc.: what insiders have been doing
Insider filings for Polaryx Therapeutics, Inc. are scarce in the SEC (Form 4) feed, the latest one published on 20 February 2026. This page will fill in as new trades are disclosed. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -22.3%Entry US$2.47 · Close 19 Oct 2026 US$1.92
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 2,867 shares@ US$2.7871100.0% of flowCommon StockSEC:0001213900-26-018845:0Canonical exit: 19 May 2026 (T+90)
1 of 1 declaration
About Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for rare diseases. It is listed on NASDAQ under the ticker PLYX.
